000			01655 a2200457 4500
005			20250516231523.0
264		0	_c20150608
008			201506s 0 0 eng d
022			_a1473-6586
024	7		_a10.1097/MOU.0000000000000105 _2doi
040			_aNLM _beng _cNLM
100	1		_aGartrell, Benjamin A
245	0	0	_aPathologic fracture in patients with metastatic prostate cancer. _h[electronic resource]
260			_bCurrent opinion in urology _cNov 2014
300			_a595-600 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAndrostenes _xtherapeutic use
650	0	4	_aAnilides _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzamides
650	0	4	_aBone Density Conservation Agents _xtherapeutic use
650	0	4	_aBone Neoplasms _xdrug therapy
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aFractures, Spontaneous _xprevention & control
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aMale
650	0	4	_aNitriles
650	0	4	_aPhenylthiohydantoin _xanalogs & derivatives
650	0	4	_aProstatic Neoplasms _xpathology
650	0	4	_aProstatic Neoplasms, Castration-Resistant _xpathology
650	0	4	_aPyridines _xtherapeutic use
650	0	4	_aRadioisotopes
650	0	4	_aRadium
650	0	4	_aZoledronic Acid
700	1		_aSaad, Fred
773	0		_tCurrent opinion in urology _gvol. 24 _gno. 6 _gp. 595-600
856	4	0	_uhttps://doi.org/10.1097/MOU.0000000000000105 _zAvailable from publisher's website
999			_c24138844 _d24138844